Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4463 |
Rucaparib
AG-14447,PF-01367338,瑞卡帕布,AG014699 |
PARP | Chromatin/Epigenetic; DNA Damage/DNA Repair |
Rucaparib (PF-01367338) 是一种口服有效的 PARP 蛋白抑制剂,对 PARP-1 的 Ki 为 1.4 nM。它是六磷酸己糖脱氢酶 (H6PD) 抑制剂,有用于去势抵抗性前列腺癌 (CRPC) 的研究潜力。 | |||
T16807 |
Rucaparib monocamsylate
瑞卡帕布樟脑磺酸盐,Rucaparib Camsylate |
PARP | Chromatin/Epigenetic; DNA Damage/DNA Repair |
Rucaparib monocamsylate (Rucaparib Camsylate) 是一种口服有效的 PARP 蛋白抑制剂,对 PARP-1 的Ki 为 1.4 nM。它是六磷酸己糖脱氢酶 (H6PD) 抑制剂,有用于去势抵抗性前列腺癌 (CRPC) 的研究潜力。 | |||
T6127 |
Rucaparib Phosphate
AG-014699 phosphate,PF-01367338,芦卡帕利,AG-014699,瑞卡帕布磷酸盐,PF-01367338 phosphate |
PARP | Chromatin/Epigenetic; DNA Damage/DNA Repair |
Rucaparib Phosphate (PF-01367338 phosphate) 是一种口服有效的PARP 蛋白抑制剂,对 PARP-1 的Ki 为 1.4 nM。它是六磷酸己糖脱氢酶 (H6PD) 抑制剂,有用于去势抵抗性前列腺癌 (CRPC) 的研究潜力。 | |||
T63065 |
Rucaparib tartrate
|
||
Rucaparib (AG014699) tartrate 是一种口服具有活力的 PARP 蛋白 (PARP-1, PARP-2 和 PARP-3) 抑制剂,作用于 PARP-1 (Ki: 1.4 nM)。Rucaparib tartrate 是一种六磷酸己糖脱氢酶 (H6PD) 抑制剂。Rucaparib tartrate 具有潜力用于去势抵抗性前列腺癌 (CRPC) 的研究。 | |||
T64289 | Rucaparib camsylate | ||
Rucaparib (AG014699) camsylate 是一种口服具有活力的 PARP 蛋白 (PARP-1、PARP-2 及 PARP-3) 抑制剂,对 PARP-1 的 Ki=1.4 nM。Rucaparib camsylate 是一种六磷酸己糖脱氢酶 (H6PD) 抑制剂。Rucaparib camsylate 具有潜力进行去势抵抗性前列腺癌 (CRPC) 的研究研究。 | |||
T61657 | Rucaparib acetate | ||
Rucaparib (AG014699) acetate is a highly effective oral inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP1. Additionally, it exhibits inhibitory action on hexose-6-phosphate dehydrogenase (H6PD) to a moderate extent. Rucaparib acetate shows promise in the field of research for castration-resistant prostate cancer (CRPC). [1] [2] [3] [4] | |||
T61335 |
Rucaparib hydrochloride
|
||
Rucaparib hydrochloride, also known as AG014699, is a powerful and orally active compound that inhibits PARP proteins including PARP-1, PARP-2, and PARP-3 with a Ki value of 1.4 nM for PARP1. Additionally, Rucaparib hydrochloride acts as a modest inhibitor of hexose-6-phosphate dehydrogenase (H6PD). This compound shows potential in research for castration-resistant prostate cancer (CRPC) [1] [2] [3] [4]. | |||
T13737 |
iRucaparib-AP6
|
Others | Others |
iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1. iRucaparib-AP6 is a highly efficient and specific PARP1 degrader based on Rucaparib by using the PROTAC approach. | |||
T39806 |
Pomalidomide 4'-PEG3-azide
Pomalidomide 4'-PEG3-azide |
||
Pomalidomide 4'-PEG3-azide is a chemically synthesized conjugate consisting of an E3 ligase ligand-linker conjugate that incorporates the cereblon ligand derived from Pomalidomide, along with a linker. This compound, Pomalidomide 4'-PEG3-azide, is utilized in the synthesis of iRucaparib-TP3 (Compound 3). iRucaparib-TP3, developed through the PROTAC strategy, is an effective degrader of PARP1, derived from Rucaparib. |